1346233-68-8

1346233-68-8

中文名称1346233-68-8
中文同义词化合物 T12076L
英文名称3,5-Dichloro-N-[[(1α,5α,6-exo,6α)-3-(3,3-diMethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]Methyl]-benzaMide
英文同义词3,5-Dichloro-N-[[(1α,5α,6-exo,6α)-3-(3,3-diMethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]Methyl]-benzaMide;CID 45115620;ML218;VU0413807;VU0424199-1;ML 218 hydrochloride;Benzamide, 3,5-dichloro-N-[[(1α,5α,6α)-3-(3,3-dimethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-;3,5-Dichloro-N-[[(1α,5α,6-exo,6α)-3-(3,3-dimethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-benzamide hydrochloride
CAS号1346233-68-8
分子式C19H26Cl2N2O
分子量369.33
EINECS号
相关类别Aromatics, Inhibitors, Pharmaceuticals, Intermediates & Fine Chemicals
Mol文件1346233-68-8.mol
结构式1346233-68-8 结构式

1346233-68-8 性质

沸点455.5±35.0 °C(Predicted)
密度1.184±0.06 g/cm3(Predicted)
储存条件2-8°C
溶解度DMSO:可溶10mg/mL(澄清溶液)
酸度系数(pKa)13.65±0.46(Predicted)
形态粉末
颜色白色至米色

1346233-68-8 用途与合成方法

ML218 是一种有效的,选择性的和口服活性的 T 型 Ca2+ 通道 (Cav3.1,Cav3.2,Cav3.3) 抑制剂,对 Cav3.2 和 Cav3.3 的 IC50 分别为 310 nM 和 270 nM。ML218 抑制丘脑底核 (STN) 神经元的爆发活动。ML218 对 L 或 N 型钙通道,KATP 或 hERG 钾通道无明显抑制作用。ML218 可以穿透血脑屏障。

IC50: 310 nM (Cav3.2), 270 nM (Cav3.3), and 150 nM (Ca 2+ flux)

In plasma protein binding studies (equilibrium dialysis), ML218 possesses good free fraction in both rat and human. Intrinsic clearance experiments in liver microsomes indicated that ML218 is highly cleared in rat (CL int = 115 mL/min/kg), but low to moderately cleared in human liver microsomes (CL int = 12.7 mL/min/kg).

ML218 (0.03-30 mg/kg; oral administration; once; male Sprague-Dawley rats) treatment reverses cataleptic behavior in rats induced by a 0.75 mg/kg dose of haloperidol.
Free brain and plasma concentrations of ML218 increases in a dose proportional manner across the dose range (3 mg/kg: [plasma] = 98 nM, [brain] = 1.66 μM; 10 mg/kg: [plasma] = 282 nM, [brain] = 5.03 μM; 30 mg/kg: 1.2 μM, [brain] = 17.7 μM).
Noncompartmental pharmacokinetic analysis indicates ML218 (1 mg/kg, IV) has a mean residence time (MRT) of nearly 7 h, a value which is consistent with its terminal half-life (t 1/2 = 7 h).

Animal Model: Male Sprague-Dawley rats (275-299 g) induced by haloperidol
Dosage: 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg
Administration: Oral administration; once
Result: Reversed cataleptic behavior in rats induced by a 0.75 mg/kg dose of haloperidol.

安全信息

WGK Germany3

MSDS信息

更新日期产品编号产品名称CAS号包装价格
2024/01/25HY-103309ML2181 mg818元
2024/01/25HY-1033091346233-68-8
ML218
1346233-68-85mg1800元

1346233-68-8 上下游产品信息

"1346233-68-8"相关产品信息
主页 | 企业会员服务 | 广告业务 | 联系我们 | 旧版入口 | 中文MSDS | CAS Index | 常用化学品CAS列表 | 化工产品目录 | 新产品列表 | 评选活动 | HS海关编码 | MSDS查询 | 化工站点

Copyright © 2016-2023 ChemicalBook 版权所有  京ICP备07040585号  京公海网安备11010802032676号  

互联网增值电信业务经营许可证:京ICP证150597号  互联网药品信息服务资格证编号(京)-非经营性-2015-0073  信息系统安全等级保护备案证明(三级)  营业执照公示

根据相关法律法规和本站规定,单位或个人购买相关危险物品应取得有效的资质、资格条件。
参考《应急管理部等多部门关于加强互联网销售危险化学品安全管理的通知 (应急〔2022〕119号)》《互联网危险物品信息发布管理规定》